INDICATIONS AND USAGE（适应症）

LORBRENA® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

DOSAGE（服用剂量）

Select patients for the treatment of metastatic NSCLC with LORBRENA based on the presence of ALK positivity in tumor specimens.

Recommended Dosage

The recommended dosage of LORBRENA is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.

Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if tablets are broken, cracked, or otherwise not intact.

Take LORBRENA at the same time each day. If a dose is missed, then take the missed dose unless the next dose is due within 4 hours. Do not take 2 doses at the same time to make up for a missed dose.

Do not take an additional dose if vomiting occurs after LORBRENA but continue with the next scheduled dose.

ADVERSE REACTIONS（不良反应）

Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers

Central Nervous System Effects

Hyperlipidemia

Atrioventricular Block

Interstitial Lung Disease/Pneumonitis

Hypertension

Hyperglycemia

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/2b34d62d-e02a-4af3-bc0d-1571dd4ee76d/spl-doc?hl=Lorlatinib

Lorviquainformation